RxDoctor Payments Data

Jillian Degraide, APRN

Primary Care · Cranston, RINPI 1023885688

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $222, 4.2 times the $52 reported in 2023.

$349in general payments, 2019–2025

Across 18 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$68
  • Pfizer$57
  • Neurocrine Biosciences, Inc.$39
  • Ardelyx, Inc.$38
  • Otsuka America Pharmaceutical, Inc.$35
  • Sumitomo Pharma America, Inc.$22
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$349 in reported general payments places this provider in the 55th percentile of 20 primary care providers in Rhode Island.

See all primary care providers in Rhode Island

Medicare billing

Part B allowed, 2024
$5,393
Medicare patients
41
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$17,961
Lacosamide41$10,327
GemtesaVibegron11$3,292
Scopolamine18$1,962
Lorazepam80$1,629
Carbidopa-LevodopaCarbidopa/Levodopa17$1,539
Atorvastatin Calcium108$1,527
Mirtazapine50$1,272
Pantoprazole Sodium22$1,128
Levothyroxine Sodium124$1,123
Escitalopram Oxalate56$894
Sertraline Hcl57$887
Clonazepam49$796
Metoprolol Succinate26$775
Ezetimibe20$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$17,96143 claims
Sumitomo Pharma America, Inc.Gemtesa$22$3,29211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 20 primary care providers in Rhode Island.

Other primary care in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →